Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,147.92 -13.95 -0.65%
FTSE 100 5,356.34 +4.81 0.09%
DAX 6,323.19 -16.75 -0.26%
Ticker Volume Price Price Delta
Nikkei 8,603.16 +10.01 0.12%
TOPIX 723.17 +2.06 0.29%
Hang Seng 18,880.30 +79.36 0.42%
Gold 1,578.40 +0.46%
EUR-USD 1.2536 -0.0395%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,356.34 +0.09%
STOXX 50 2,147.92 -0.65%
DAX 6,323.19 -0.26%
Oil (WTI) 91.27 +0.45%
U.S. 10-year 1.745% +0.007
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%

Gulfo Sees FDA Getting `Back on Track' on Melanoma Test: Video

May 20 (Bloomberg) -- Joseph Gulfo, chief executive officer of Mela Sciences Inc., talks about the U.S. Food and Drug Administration's delay in approving its melanoma-detection device. Mela filed a first-of-its-kind petition to force the agency to uphold an agreement to approve the device. Gulfo speaks with Pimm Fox on Bloomberg Television's "Taking Stock." (Source: Bloomberg)

Joseph Gulfo, chief executive officer of Mela Sciences Inc., talks about the U.S. Food and Drug Administration's delay in approving its melanoma-detection device.

Mela filed a first-of-its-kind petition to force the agency to uphold an agreement to approve the device. Gulfo speaks with Pimm Fox on Bloomberg Television's "Taking Stock." (Source: Bloomberg)

Running time 05:09

Sponsored Links